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Non-specific effects of vaccination
Vaccines have non-specific (heterologous)
effects
Editor—I support Fine’s plea that we review
the optimal immunisation schedule in
developing countries using evidence from
controlled trials rather than observational
data.1 There are almost no controlled trials
of the effect on mortality from all causes for
any of the vaccines in the World Health
Organization’s schedule.
Fine says, incorrectly, that literature does
not support non-specific effects of vaccines.
Firstly, BCG protects against leprosy and
is the treatment of choice for some types of
bladder cancer.2
Secondly, an individual’s
history of previous infection
or immunisation can clearly
influence the response to
subsequent infections—
immunologists call this heter-
ologous immunity, rather
than non-specific immunity.3 4
Thirdly, evidence that
vaccines have heterologous
effects comes from control-
led trials, and not just obser-
vational studies.5
It is important to be clear
about what is meant by the
hypothesis that vaccines have
heterologous (non-specific) effects. The
hypothesis says that in high mortality areas,
vaccines may affect mortality from diseases
other than the target disease (for example,
measles vaccine may reduce mortality from
infectious diseases other than measles);
these effects are much stronger in girls than
boys; they are strongest in the first three to
six months after immunisation; and they are
largely determined by the most recent
vaccine received.
The immunological basis of heterolo-
gous immunity is now well established,3 4
and this knowledge should be used to help
design controlled trials to determine the
optimal immunisation schedule for children
in developing countries. Millions of lives
could be saved.
Frank Shann director of intensive care
Intensive Care Unit, Royal Children’s Hospital,
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Author’s reply to Shann
Editor—Shann rightly questions the sub-
title to my editorial, “Literature does not
support either beneficial or detrimental
effects.” I did not write it and failed to note its
insertion by the editor at the last moment
before the article went to
press—for which I apologise.
Of course, there are
many well documented non-
specific effects of vaccines,
two of which I mentioned
explicitly: “Some vaccines
have effects on non-target
diseases—for example, BCG
protects against leprosy.
Some vaccines have rare
adverse reactions—for exam-
ple, myopericarditis after
smallpox vaccine.”
The existence of some
non-specific effects is not an
issue—and they extend far
beyond the limits of the hypothesis pro-
posed in Shann’s letter. My scepticism was,
and remains, aimed at the spate of studies
on the supposed “non-specific effects” (both
beneficial and detrimental) of vaccines on
mortality, typified by the paper by Vauge-
lade et al and several by Aaby et al.1 2 3
These studies faced very difficult meth-
odological challenges and have been unable
convincingly to get round the obvious huge
confounding associated with the selective
distribution of vaccines. Given that con-
founding, the only way rigorously to study
such outcomes is by trials, and these may be
justified not only to study these proposed
non-specific effects (some will believe there
is insufficient a priori evidence of such
effects to justify the cost of trials) but to
compare different vaccine regimens and
timetables, and with specific disease inci-
dence as well as non-specific morbidity and
mortality among the measured outcomes.
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Survival bias may explain findings
Editor—Vaugelade et al found the BCG
and diphtheria-tetanus and pertussis vac-
cines (DTP) to be associated with reductions
in mortality greater than expected from dis-
ease prevention.1 However, as they admit,
dead vaccinated children may have been
misclassified because their vaccination cards
were destroyed.
In a survival analysis using vaccination
dates as time dependent covariates, surviv-
ing children change status at date of
vaccination even though vaccinations were
only known later, whereas dead vaccinated
children and their follow up time remain in
the unvaccinated group.2 3 As a result, risk
free survival time will be allocated to the
vaccinated group, creating survival bias.2
Consequently, mortality is too high in
unvaccinated children; 45% of children
were vaccinated before age 6 months, but
only 12 vaccinated children died compared
with 435 unvaccinated children. This
corresponds to an unlikely mortality that is
10-15 times as high among unvaccinated
children younger than 6 months. In
contrast, mortality in Guinea-Bissau was
only twice as high.4
To control for misclassification, Vauge-
lade et al claim to replicate our analysis,
using time fixed vaccination status. However,
these analyses had several methodological
differences.4 Most importantly, we registered
non-vaccination and excluded 35% for miss-
ing information,5 whereas they did not
exclude any child.1 Hence, their “unvacci-
nated” group included unvaccinated and
children without information. This may have
inflated mortality, the rate being 129%
(76-198%) higher in unvaccinated than vac-
cinated children, compared with only 35%
( − 3-89%) in Guinea-Bissau.5 The reference
group may hence be irrelevant and the cor-
responding estimates of DTP and BCG
being associated with 50% reduction in
mortality may be misleading.1
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Vaugelade et al recognised potential
misclassification but probably underesti-
mated the effect and therefore maintained
the conclusion that BCG and DTP had ben-
eficial effects. However, introducing survival
bias in an analysis can turn a negative
estimate into a positive one and can
therefore not document non-specific effects
or provide assurance that DTP has no
increased mortality.
Peter Aaby professor
Henrik Jensen senior statistician
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Authors’ reply to Aaby et al
Editor—Aaby et al raise issues of general
rather than specific interest, as their
references indicate. The study of the
effects of vaccines, which pioneered the
randomised controlled trials method more
than 50 years ago, is still topical and of
general interest.1 The limitations discussed
by Aaby et al are intrinsic to all observa-
tional datasets and, in this respect, the assets
of our study are to rely on both indepen-
dent and shared pre-planned analyses2 of
observational datasets, issued from a
country other than Guinea-Bissau. The
simulations we performed (which are avail-
able on request) on the effects of a possible
survival bias logically influenced our esti-
mates towards 1 but did not yield different
conclusions.
In addition to the misclassification
aspect, causal inference is also an issue at
stake. In this respect, we agree with Fine that
the conclusion of our study is no evidence
for a positive association between any
vaccine and increased mortality in infants.3
Although the title of our paper mimicked
that of Aaby et al’s work on non-specific
effects of vaccines, our conclusion con-
cerned the statistical association, not the
effects. Such methodological aspects—
misclassification and bias—raised by studies
on the effects of vaccines, highlight the need
for improved surveillance and implementa-
tion of phase VI or pharmaco-
epidemiological studies in areas with high
mortality.
J Vaugelade demographer
vaugelad@ird.fr
F Simondon epidemiologist
E Elguero statistician
Institut de Recherche pour le Développement,
Laboratoire Population, Environnement et
Développement, BP 64501, 34394 Montpellier
Cedex 5, France
S Pinchinat biostatistician
Biostatem, Parc Scientifique G Besse, F 30035
Nîmes, France
G Guiella researcher
Unité d’Etudes et de Recherche en Démographie,
03 BP 7118, Ouagadougou 03, Burkina Faso
Competing interests: SP has been a consultant
statistician for Aventis Pasteur and Aventis
Pasteur MSD on pertussis, rotavirus, and herpes
zoster. EE has been funded by Aventis to attend a
meeting.
1 Lawlor DA, Smith DS, Bruckdorfer KR, Kundu D, Ebrahim
S. Those confounded vitamins: what can we learn from the
differences between observational versus randomised trial
evidence? Lancet 2004;363:1724-7.
2 World Health Organization. Workshop on child survival
and routine immunization. WHO, Geneva, 8-9 October
2001.
3 Fine P. Non-specific “non-effects” of vaccination. BMJ
2004;329:1297-1298. (4 December.)
DTP in low income countries:
improved child survival or
survival bias?
Editor—We proposed that BCG and
measles vaccine have non-specific beneficial
effects, whereas diphtheria-tetanus-pertussis
(DTP) vaccination might have no beneficial
effect.1 In response, the World Health
Organization commissioned several
studies.2–4 A WHO expert task force found
substantial evidence against a deleterious
effect of DTP; all studies showed DTP to be
associated with reduced mortality. A nega-
tive DTP effect was found only in Guinea-
Bissau, and this was presumed to be due to a
country specific issue or a peculiarity of the
data.5
In our survival analysis, vaccination
status was a time fixed variable, held
constant from the initial visit to the next;
without perfect information for all children,
vaccinations during follow-up could not be
accounted for, which means a potential
source of bias.1 In the WHO sponsored
analyses, vaccination status was a time
varying variable changing status at the date
of vaccination, based on information
achieved at a subsequent visit.2–5 We used this
approach to re-analyse our data (table).
The distribution of deaths was similar.
When we used time varying variables,
person years decreased for the unvaccinated
and BCG groups, and mortality went up.
Person years increased for the DTP groups
and mortality decreased. Hence, DTP was
associated with reductions in mortality
(table), similar to results from WHO
sponsored studies.2–4
Why this difference? Information on
vaccinations is typically collected through
periodic home visits. When a child dies, the
vaccination card is usually thrown away; and
information on vaccination is therefore col-
lected conditionally on survival to the subse-
quent visit. If an unvaccinated child was
vaccinated and died before the next visit the
death would be classified as unvaccinated, in
an analysis using time varying variables. If a
vaccinated child survived then the follow up
time as vaccinated would be moved to the
new vaccination. This survival time is risk
free—that is, we only know that the child was
vaccinated because it survived. Such survival
bias may turn a negative estimate into a
positive one: our original 84% increase in
mortality for one dose of DTP became a
32% reduction (table).
Survival bias can be avoided only if all
vaccinations are provided by the research-
ers, or perfect vaccination information is
obtained from all children. Nothing indi-
cates that these conditions were met in the
WHO commissioned studies.2–4 In contrast
Deaths and person years according to vaccination group, using vaccination status as time fixed or time
varying variable, Guinea-Bissau, 1990-6
Vaccination status as time fixed
variable
Vaccination dates as time varying
variables
Deaths
Person years
at risk
Mortality per
1000 person
years Deaths
Person years
at risk
Mortality per
1000 person
years
Vaccination status
No BCG+DTP one dose 2 9.0 222 2 16.3 123
No BCG+DTP two doses 0 4.5 0 0 3.5 0
No BCG+DTP three doses 0 1.4 0 0 4.2 0
BCG+no DTP 33 537.6 61 33 334.4 99
BCG+DTP one dose 59 595.5 99 60 679.5 88
BCG+DTP two doses 21 266.6 79 20 443.4 45
BCG+DTP three doses 12 119.6 100 15 425.0 35
Vaccinated 127 1534.2 83 130 1906.3 68
Unvaccinated 95 875.1 109 92 503.0 183
All 222 2409.3 92 222 2409.3 92
Mortality ratio (95% CI)
Unvaccinated v vaccinated 1.35 (0.97 to 1.89) 2.96 (2.15 to 4.08)
BCG v BCG unvaccinated 0.55 (0.36 to 0.85) 0.62 (0.41 to 0.92)
One dose DTP v DTP unvaccinated 1.84 (1.10 to 3.10) 0.68 (0.44 to 1.04)
Two doses DTP v DTP unvaccinated
1.38 (0.73 to 2.61)*
0.26 (0.15 to 0.47)
Three doses DTP v DTP unvaccinated 0.16 (0.08 to 0.32)
*Two and three doses of DTP were combined in original study.1
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to our study, none of the WHO studies
documented which children were unvacci-
nated; they do not distinguish between
“unvaccinated” and “no information.” The
contradiction between our study and the
WHO sponsored studies might be due to
methodological differences and not peculi-
arity of the data.
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Phenobarbital for epilepsy:
much is still to be learnt
Editor—Kale and Perucca contrast the
widespread use of phenobarbital for epi-
lepsy in the developing world with its
disfavour in the developed world.1
In the developing world up to two thirds
or more of people with epilepsy receive no
treatment at all.2 With limited resources and
infrastructure health authorities’ promotion
of a cheap but effective drug, phenobarbital,
is understandable and desirable. In devel-
oped countries the problem is often
overtreatment. In the United Kingdom
three other standard anti-epileptic drugs
(phenytoin, carbamazepine, valproate) have
been joined by eight new anti-epileptic
drugs in the past 15 years. Polytherapy is
increasing. Many doctors are bewildered
by the potential choice of drug or drug
combinations.
My colleagues and I conducted one of
the few randomised efficacy and toxicity
studies comparing phenobarbital with other
standard anti-epileptic drugs.3 4 In adults
and children with newly diagnosed general-
ised or partial seizures long term efficacy
was similar for phenobarbital, phenytoin,
carbamazepine, and valproate. Neurotox-
icity of phenobarbital was only slightly
greater in adults but much greater in
children. Phenobarbital remains useful in
adults but should be used with caution in
children if it is the only available drug.When
a single drug fails doctors still do not know
whether combining two drugs is better than
another single drug, or which combination
of two drugs is best.5
After more than 80 years much is still to
be learnt about phenobarbital, the most
widely used anti-epileptic drug in the world.
The same is true of the standard and newer
drugs, and of any combination. To expect
the World Health Organization or the Inter-
national League Against Epilepsy (ILAE) to
undertake the necessary clinical trials and
basic research is unrealistic.WHO is a public
health organisation which promotes best
practice within limited existing knowledge
and resources, as in the global campaign
against epilepsy.2 Indeed, scientific institu-
tions in the developing world should under-
take such studies, either alone or in
collaboration with similar institutions in the
developed world, especially designated
WHO collaborating centres.
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Use of chaperones in general
practice
GPs try to balance doctors’ and patients’
needs
Editor—In two separate papers Rosenthal
et al and Conway and Harvey studied the
use of chaperones in general practice
settings.1 2 Conway and Harvey say that
chaperones are used for the protection of
the doctor rather than the patient. We have
found that practitioners who perform
vaginal examinations feel that they are
juggling competing interests when deciding
on the offering and use of a chaperone.
We interviewed primary care practition-
ers about their approach to the manage-
ment of menstrual disorders.3 The role of
the chaperone was understood as both pro-
tecting the doctor and reducing the patient’s
perception of vulnerability. Practitioners
were aware of the guidelines produced by
professional bodies and the potential
medicolegal consequences of not using a
chaperone. A chaperone could, however,
adversely affect patient and consultation.
In keeping with general social percep-
tions, female patients being examined by
male doctors were considered most vulner-
able and hence in most need of a chaperone.
Protecting the patient from vulnerability
and embarrassment required that the chap-
erone be of the same sex as the patient. The
use of a male chaperone for the examina-
tion of a female patient or of a female chap-
erone when a male patient was being
examined was judged inappropriate by
interviewees of both sexes.
For many practitioners, blanket guide-
lines were a source of stress. In primary care,
where patients may choose the doctor they
see, practitioners judged that many patients
had already made a decision about which
doctor they felt comfortable consulting.
Suggesting that a chaperone might be
required was perceived as introducing into a
previously good relationship between doc-
tor and patient the idea that the doctor was
not trustworthy. More experienced practi-
tioners argued that the key to reducing diffi-
culties for practitioners and patients lay in
better communication training.
Norma O’Flynn clinical lecturer in general practice
Charing Cross Campus, Imperial College London,
London W6 8RP
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Chaperones protect both parties
Editor—The two papers on the use of
chaperones in general practice are relevant
to genitourinary medicine (GUM) clinics,
where intimate examinations are routine.1 2
In response to recent guidance we published
and repeated a survey on patients’ prefer-
ences for chaperones (table).3–5
Doctors completed proformas before
intimate examinations of patients, over con-
secutive sessions from June to December
2003. Patients declined chaperones because
they trusted the doctor, thought it unneces-
sary, wanted privacy, were embarrassed, or
were not bothered. Ninety two per cent of
patients (232/252) were offered a chaper-
one; 22% (52) accepted, 12% (27) expressed
no preference, and 66% (153) declined.
Significantly fewer male patients
accepted chaperones than female patients
(3.0%, 95% confidence interval 0.6% to 8.4%,
and 37.4%, 29.1% to 45.7%, respectively). Sig-
nificantly more female patients accepted
chaperones from male doctors (85.4%) than
from female doctors (9.6%; P ≤ 0.001, 2 test).
Most patients declined chaperones,
except when the doctor was male and the
patient female. We continue offering chap-
erones to all patients requiring intimate
examinations, which has not affected work-
load. However, Conway and Harvey found
Details of the three other authors are on
bmj.com
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that nearly half of male general practitioners
never and rarely used chaperones when inti-
mately examining women. Some used
receptionists as chaperones, which is unsuit-
able in genitourinary medicine.1 Rosenthal
et al found that only 37% of general
practitioners had a chaperoning policy, but
lack of staffing and resources are unaccept-
able excuses.2
Doctors who continue performing inti-
mate examinations unchaperoned risk alle-
gations of misconduct.5 Chaperones are
there for the protection of both parties. Per-
haps further guidance will arise for other
healthcare professionals, who until now may
see patients unaccompanied.
Charlotte Cohen specialist registrar GU/HIV
medicine
cemcohen@hotmail.com
Ken McLean consultant GU/HIV medicine
West London Centre for Sexual Health, Charing
Cross Hospital, London W6 8RF
Simon Barton clinical director, department of
GU/HIV medicine
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Ethics and research
governance in a multicentre
study: add 150 days to your
study protocol
Editor—Concern is growing that health
service research will be impeded by
“research governance” procedures, in addi-
tion to the difficulties of gaining ethical
approval.1–3 We describe the problems expe-
rienced by an evaluation study team (funded
by the Service Delivery and Organisation
Research Programme) that wanted to assess
the impact of modernising endoscopy serv-
ices in 20 NHS Trusts in England. Ethical
approval was given by a multicentre
research ethics committee in 47 working
days. Achieving research governance
approval was more difficult.
The study used postal surveys of patients
to assess the impact of endoscopy service
innovations on waiting times and other out-
comes, using validated quality of life, patient
satisfaction instruments, and health eco-
nomic data. A qualitative component used
interviews with clinicians, change agents,
and patients. No experimental intervention
was undertaken.
The range of familiarity with research
governance “approval” procedures in NHS
trusts was wide, from full awareness to total
ignorance, illustrated by two trusts providing
immediate verbal approval. Substantial vari-
ation occurred in the application proce-
dures. Many trusts required more informa-
tion than the ethics committee, such as
confirmation of sponsor and copies of peer
review reports (often not made available to
researchers). Documentation was “lost” in
two trusts.
Some trusts gave approval authority to
one person while others relied on research
and development committees, which typi-
cally sat monthly. These committees often
had long lead times and full agendas, result-
ing in delays. One such trust committee
imposed its own “research” conditions, alter-
ing the protocol and leading to the site
being abandoned, to the dismay of the trust
clinician who wanted to participate.
In summary, the research governance
framework has been interpreted in many
different ways.4 5
The figure shows the number of working
days from application to final approval. The
median time to approval was 61 days (95%
confidence interval 51 to 81 days); the most
time taken was 103 days (equivalent to 5
months). Applications took place from
November 2003 to March 2004, and to
exclude the possibility of improvements tak-
ing place over time we estimated a possible
correlation (Spearman’s r) between the
order of the application and the time taken.
We found a non-significant (P = 0.22) nega-
tive correlation (r= − 0.28), indicating that
order had no effect.
Obtaining research governance
approval for all 20 NHS trusts required 103
days. This is a rate limiting step, as a simulta-
neous start was needed across all 20 sites.
With the addition of the 47 days taken to
obtain ethical approval, this resulted in a
total delay of 150 days.
Research studies requiring multiple
NHS sites should build in substantial lag
times before research processes can be initi-
ated. We anticipate that failure to address
this new obstacle to health service research
will block evaluation work and accelerate the
migration of clinical studies to other parts of
the world.
Glyn Elwyn professor
glyn.elwyn@btinternet.com
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Results of chaperoning survey. Values are numbers of patients unless otherwise indicated
Type of consultation
Patients seen by
doctor Chaperone not offered Chaperone offered
Chaperone accepted
(%)
Female patient:
Female doctor 93 10* 83 8 (9.6)
Male doctor 56 8† 48 41 (85.4)
Male patient:
Female doctor 44 2‡ 42 1 (2.4)
Male doctor 59 0 59 2 (3.4)
*No reason given (6), doctor forgot (1), language difficulties (1), mother present (1), sexual assault (1).
†Considered necessary because of male doctor.
‡ Doctor forgot (1), examined by male doctor instead (1).
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